CRR9/CLPTM1L Regulates Cell Survival Signaling and Is Required for Ras Transformation and Lung Tumorigenesis

被引:53
作者
James, Michael A. [1 ]
Vikis, Haris G. [1 ]
Tate, Everett [1 ]
Rymaszewski, Amy L. [1 ]
You, Ming [1 ]
机构
[1] Med Coll Wisconsin, Dept Pharmacol & Toxicol, MCW Canc Ctr, Milwaukee, WI 53226 USA
关键词
GENOME-WIDE ASSOCIATION; CANCER-RISK; SUSCEPTIBILITY LOCI; CHINESE POPULATION; INDUCED APOPTOSIS; GENETIC-VARIATION; PI3K/AKT PATHWAY; TELOMERE LENGTH; 5P15.33; VARIANTS;
D O I
10.1158/0008-5472.CAN-13-1617
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transmembrane protein CLPTM1L is overexpressed in non-small cell lung cancer, where it protects tumor cells from genotoxic apoptosis. Here, we show that RNA interference-mediated blockade of CLPTM1L inhibits K-Ras-induced lung tumorigenesis. CLPTM1L expression was required in vitro for morphologic transformation by H-RasV12 or K-RasV12, anchorage-independent growth, and survival of anoikis of lung tumor cells. Mechanistic investigations indicated that CLPTM1L interacts with phosphoinositide 3-kinase and is essential for Ras-induced AKT phosphorylation. Furthermore that the anti-apoptotic protein Bcl-xL is regulated by CLPTM1L independently of AKT activation. Constitutive activation of AKT or Bcl- xL rescued the transformed phenotype in CLPTM1L-depleted cells. The CLPTM1L gene lies within a cancer susceptibility locus at chromosome 5p15.33 defined by genome-wide association studies. The risk genotype at the CLPTM1L locus was associated with high expression of CLPTM1L in normal lung tissue, suggesting that cis-regulation of CLPTM1L may contribute to lung cancer risk. Taken together, our results establish a protumorigenic role for CLPTM1L that is critical for Ras-driven lung cancers, with potential implications for therapy and chemosensitization. (C) 2013 AACR.
引用
收藏
页码:1116 / 1127
页数:12
相关论文
共 45 条
[1]   Network organization of the human autophagy system [J].
Behrends, Christian ;
Sowa, Mathew E. ;
Gygi, Steven P. ;
Harper, J. Wade .
NATURE, 2010, 466 (7302) :68-U84
[2]   The PKB/AKT Pathway in Cancer [J].
Carnero, Amancio .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (01) :34-44
[3]   Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy [J].
Chaparro, J ;
Reeds, DN ;
Wen, WD ;
Xueping, E ;
Klein, S ;
Semenkovich, CF ;
Bae, KT ;
Quirk, EK ;
Powderly, WG ;
Yarasheski, KE ;
Li, E .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (05) :561-567
[4]   Prevalence of Telomerase Activity in Human Cancer [J].
Chen, Chi-Hau ;
Chen, Ruey-Jien .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2011, 110 (05) :275-289
[5]   The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL [J].
Chen, CL ;
Edelstein, LC ;
Gélinas, C .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) :2687-2695
[6]   Multiple variants of TERT and CLPTM1L constitute risk factors for lung adenocarcinoma [J].
Chen, X. F. ;
Cai, S. ;
Chen, Q. G. ;
Ni, Z. H. ;
Tang, J. H. ;
Xu, D. W. ;
Wang, X. B. .
GENETICS AND MOLECULAR RESEARCH, 2012, 11 (01) :370-378
[7]   Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma [J].
Du, X-L ;
Yang, H. ;
Liu, S-G ;
Luo, M-L ;
Hao, J-J ;
Zhang, Y. ;
Lin, D-C ;
Xu, X. ;
Cai, Y. ;
Zhan, Q-M ;
Wang, M-R .
ONCOGENE, 2009, 28 (42) :3714-3722
[8]   Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase [J].
DuPage, Michel ;
Dooley, Alison L. ;
Jacks, Tyler .
NATURE PROTOCOLS, 2009, 4 (07) :1064-1072
[9]   Association of the 15q25 and 5p15 Lung Cancer Susceptibility Regions with Gene Expression in Lung Tumor Tissue [J].
Fehringer, Gord ;
Liu, Geoffrey ;
Pintilie, Melania ;
Sykes, Jenna ;
Cheng, Dangxiao ;
Liu, Ni ;
Chen, Zhuo ;
Seymour, Lesley ;
Der, Sandy D. ;
Shepherd, Frances A. ;
Tsao, Ming-Sound ;
Hung, Rayjean J. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (07) :1097-1104
[10]   Regulation of Bcl-xL:: a little bit of this and a little bit of STAT [J].
Grad, JM ;
Zeng, XR ;
Boise, LH .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) :543-549